Achilles Therapeutics

Risk score

57
Large logo of Achilles Therapeutics

Headquarters

Flag of United KingdomUnited Kingdom

Achilles Therapeutics is a biopharmaceutical firm that is in the process of developing innovative cancer immunotherapies that target clonal neoantigens. These are protein markers that are distinct to each person and are visible on the surface of every cancerous cell. Achilles leverages genetic sequencing information from each patient, in conjunction with its unique bioinformatics platform, to pinpoint clonal neoantigens specific to that patient. This, in turn, facilitates the creation of personalized cellular treatments. By targeting multiple clonal neoantigens found on all cancer cells, but not on healthy ones, tailored therapies can effectively eradicate tumors without causing harm to healthy tissues.